Chromadex Corp (CDXC.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2015||Independent Chairman of the Board|
|58||2018||President, Chief Strategy Officer, Chief Operating Officer, Director|
|48||2017||Chief Executive Officer, Independent Director|
|60||2017||Chief Financial Officer, Secretary, Principal Accounting Officer and Principal Financial Officer|
|44||2018||Executive Vice President|
- BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17
- BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board
- BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln
- BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent
- BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore